Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Carol Stiff

- PMLiVE

Kinarus’ KIN001 shows strong antiviral activity against BA.2 and BA.5 Omicron subvariants

The phase 2 trial of KIN001 in ambulatory COVID-19 patients is actively recruiting

How to Increase Engagement During Virtual Events

Tip #2 - Are you team ""jump on a call"" or team ""just email me""? Instead of choosing just one, try using a combination of synchronous (real-time) and asynchronous (over-time,...

Impetus Digital

How the Legally Blind Can Achieve Enhanced Vision

Roland Mattern, Director of Product Marketing at eSight Eyewear, shares how eSight’s technologies are being used to bring sight back to people living with central vision loss. He also discusses...

Impetus Digital

Can Cinderella save us?

UK government launches consultation on silent AMR pandemic

The consultation will call upon the latest data from experts on antimicrobial resistance

How to Increase Engagement During Virtual Events

Tip #1 - How can you take your online presentations to the next level? Check out the full list of top 10 tips to increase engagement during virtual events: https://www.impetusdigital.com/2021/03/25/top-10-tips-to-increase-engagement-during-virtual-events/

Impetus Digital

- PMLiVE

Moderna’s bivalent Omicron-targeting boosters show superiority to original COVID-19 vaccine

Both boosters produced a better immune response against Omicron BA.4/BA.5 subvariants

- PMLiVE

NICE publishes draft guidance recommending three COVID-19 treatments

Five treatments have not been recommended for use, with the organisation citing cost-effectiveness concerns

- PMLiVE

WHO, WIPO and WTO to hold technical symposium on pandemic preparedness

The event will examine ways to build resilience to be better prepared for future pandemics

- PMLiVE

CDC shows new BQ.1 and BQ 1.1 Omicron subvariants account for 44% of US COVID-19 cases

The two new variants accounted for over 32% of US cases the prior week

- PMLiVE

Pfizer/BioNTech BA.4/BA.5 COVID-19 booster receives CHMP recommendation for children five to 11 years

If an authorisation is granted, doses of the bivalent booster will be available to all 27 EU member states

- PMLiVE

Sanofi/GSK’s next-generation COVID-19 booster granted EC approval

Two trials compared the immune response induced by VidPrevtyn Beta with approved vaccines

- PMLiVE

Novavax’s COVID-19 vaccine receives MHRA approval for use as a booster

Nuvaxovid was shown to increase antibody levels when used as a third booster

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links